HANSOH PHARMA (03692): Xin Yue (Inalimumab injection) new indications included in the priority review and approval process.

HANSOH PHARMA (03692) announced that on February 8, 2025, based on Xinyue.

Zhitong FinanceFeb 9 19:40 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

Hansoh Pharmaceutical Group's (HKG:3692) Investors Will Be Pleased With Their Favorable 55% Return Over the Last Year

Simply Wall StJan 30 02:06 ET

BOCOM INTL: Expectations for the implementation of Class C medical insurance catalog have further increased this year, giving a "leading" rating to the mainland Pharmaceutical Industry.

A "leading" rating is given to the domestic pharmaceutical Industry, with a focus on Innovation and valuation recovery as the two main lines. The expectation for the implementation of the Category C medical insurance directory within the year has further increased, which is expected to support the establishment of a diversified payment mechanism for Innovative Drugs.

Zhitong FinanceJan 27 03:33 ET

[Brokerage Focus] BOCOM INTL indicates that the expectation for the implementation of Category C medical insurance catalog enhances the catalyzing sentiment and repairs focus on innovation and valuation recovery opportunities.

Jinwu Financial News | BOCOM INTL indicates that the expectation for the implementation of the Class B medical insurance catalog has further increased this year, and it is expected to support the establishment of diversified payment mechanisms for Innovative Drugs. At the same time, the initiation of the immediate settlement reform for the medical insurance fund is expected to alleviate the cash pressure on Medical Institutions. Combined with the fact that the continued procurement of various medicines and devices has created financial space for payment of Innovative Drugs, the subsequent introduction of favorable policies from fiscal and Medical / commercial insurance is ongoing, and valuations remain at historical lows, the bank believes the Sector still has significant room for recovery. The bank continues to focus on recommending potential beneficiary symbols for the subsequent policy space, including: 1) AKESO (09926), INNOVENT BIO (01.

Jinwu Financial NewsJan 26 19:38 ET

Hansoh Pharma Announces Key Corporate Secretariat Changes

TipRanksJan 24 04:07 ET